Click Therapeutics raises $30 million in debt to advance commercialization of smoking cessation app Clickotine

Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations (press release): Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics solutions as prescription medical treatments, today announced $30 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, to accelerate commercialization of its leading smoking cessation solution, Clickotine, and to advance its pipeline of clinically-validated digital therapeutics… Click Therapeutics has recently announced the achievement of key corporate milestones, including securing significant new distribution partners for Clickotine as well as finalizing a landmark co-development and commercialization partnership in schizophrenia with Boehringer Ingelheim. The company is developing a broad pipeline of prescription digital therapeutics for the treatment of indications across multiple therapeutic areas, from psychiatry and chronic pain to cardiometabolic and autoimmune disorders. “We have been evaluating the space of digital therapeutics for some time and decided now is the time to invest in support of an industry leader. Click’s platform-based approach enables targeting of a wide variety of different indications, and its multiple commercial and co-development collaborations support a global reach,” said Parag Shah, Founding Managing Director and Chief Executive Officer of K2HV. News in Context: Click Therapeutics and Boehringer Ingelh...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Technology & Innovation Click Therapeutics Clickotine digital therapeutics K2 HealthVentures medical treatments neurotechnologies non-invasive neurotechnologies prescription Source Type: blogs